Mounjaro and Trulicity are two injectable medications that treat type 2 diabetes. Learn more about their key similarities, ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Tirzepatide — a drug that acts both as a GLP-1 agonist and a GIP agonist — is the active ingredient in an even more powerful ...

Viking Therapeutics' plans to launch VK2735 with an auto-injector could delay regulatory approval. Click here to read why ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...

Eli Lilly launches Mounjaro in India addressing diabetes-obesity crisis. Approved by CDSCO yet high costs limit accessibility ...

Mounjaro (tirzepatide) is an FDA-approved antidiabetic injection gaining popularity for its effectiveness in weight ...

Roche and Oxford BioTherapeutics (OBT) have entered into a partnership worth over $1bn to discover new antibody-based ...

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. Priced at Rs 3,500 for a 2.5 mg vial, the ‘game-changing’ medication has debuted in the Indian ...

Eli Lilly launches Mounjaro, the much-awaited diabetes drug, in India. It is priced at ₹3,500 for 2.5 mg. Mounjaro and ...